Eliyatkın Nuket, Yalçın Evrim, Zengel Baha, Aktaş Safiye, Vardar Enver
Department of Pathology, İzmir Bozyaka Training and Research Hospital, İzmir, Turkey.
Department of Pathology, Erciş State Hospital, Van, Turkey.
J Breast Health. 2015 Apr 1;11(2):59-66. doi: 10.5152/tjbh.2015.1669. eCollection 2015 Apr.
Breast carcinoma comprises a group of diseases with specific clinical, histopathologic and molecular properties. Traditional classification use morphology to divide tumors into separate categories with differing behavior and prognosis. However, there are limitations of traditional classification systems, and new molecular methods are expected to improve classification systems. Molecular subtypes of breast carcinomas have been characterized in the last 11 years, and have been studied extensively. Much of the information accumulated in recent years, and molecular taxonomy seems to be still developing and undergoing change. The main question is whether new molecular techniques such as gene expression profiling will be accepted as gold standard in determining breast cancer subtypes, and whether molecular classification is useful in specific subtypes of breast cancer as it is in ductal carcinoma (nonspecific type). In addition, critical review of the literature reveals major problems such as poor definition, lack of reproducibility and lack of quality control in current molecular techniques and classifications. Therefore, current molecular approaches are not yet used in routine clinical practice and treatment guidance since they are immature and can even lead to incorrect assessment.
乳腺癌是一组具有特定临床、组织病理学和分子特性的疾病。传统分类利用形态学将肿瘤分为具有不同行为和预后的不同类别。然而,传统分类系统存在局限性,新的分子方法有望改进分类系统。乳腺癌的分子亚型在过去11年中已得到表征,并得到了广泛研究。近年来积累了大量信息,分子分类法似乎仍在发展和变化。主要问题是诸如基因表达谱分析等新的分子技术是否会被接受为确定乳腺癌亚型的金标准,以及分子分类在乳腺癌的特定亚型中是否像在导管癌(非特殊类型)中一样有用。此外,对文献的批判性审查揭示了当前分子技术和分类中存在的主要问题,如定义不明确、缺乏可重复性和缺乏质量控制。因此,目前的分子方法尚未用于常规临床实践和治疗指导,因为它们尚不成熟,甚至可能导致错误的评估。